High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission

Arnold S. Freedman, John G. Gribben, Donna Neuberg, Peter Mauch, Robert J. Soiffer, Kenneth C. Anderson, Lini Pandite, Michael Robertson, Mary Kroon, Jerome Ritz, Lee M. Nadler

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36% achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63% and 89% at 3 years, respectively, with a median follow- up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival.

Original languageEnglish (US)
Pages (from-to)2780-2786
Number of pages7
JournalBlood
Volume88
Issue number7
StatePublished - Oct 1 1996
Externally publishedYes

Fingerprint

Follicular Lymphoma
Autologous Transplantation
Polymerase chain reaction
Bone Marrow Transplantation
Bone
Polymerase Chain Reaction
Therapeutics
Purging
Chemotherapy
Vincristine
Prednisone
Induction Chemotherapy
Survival
Doxorubicin
Cyclophosphamide
Non-Hodgkin's Lymphoma
Disease-Free Survival
Monoclonal Antibodies
Cells
B-Lymphocytes

ASJC Scopus subject areas

  • Hematology

Cite this

Freedman, A. S., Gribben, J. G., Neuberg, D., Mauch, P., Soiffer, R. J., Anderson, K. C., ... Nadler, L. M. (1996). High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood, 88(7), 2780-2786.

High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. / Freedman, Arnold S.; Gribben, John G.; Neuberg, Donna; Mauch, Peter; Soiffer, Robert J.; Anderson, Kenneth C.; Pandite, Lini; Robertson, Michael; Kroon, Mary; Ritz, Jerome; Nadler, Lee M.

In: Blood, Vol. 88, No. 7, 01.10.1996, p. 2780-2786.

Research output: Contribution to journalArticle

Freedman, AS, Gribben, JG, Neuberg, D, Mauch, P, Soiffer, RJ, Anderson, KC, Pandite, L, Robertson, M, Kroon, M, Ritz, J & Nadler, LM 1996, 'High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission', Blood, vol. 88, no. 7, pp. 2780-2786.
Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 1;88(7):2780-2786.
Freedman, Arnold S. ; Gribben, John G. ; Neuberg, Donna ; Mauch, Peter ; Soiffer, Robert J. ; Anderson, Kenneth C. ; Pandite, Lini ; Robertson, Michael ; Kroon, Mary ; Ritz, Jerome ; Nadler, Lee M. / High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. In: Blood. 1996 ; Vol. 88, No. 7. pp. 2780-2786.
@article{f99f6394cee247909c301dcbfc73800a,
title = "High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission",
abstract = "We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36{\%} achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63{\%} and 89{\%} at 3 years, respectively, with a median follow- up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival.",
author = "Freedman, {Arnold S.} and Gribben, {John G.} and Donna Neuberg and Peter Mauch and Soiffer, {Robert J.} and Anderson, {Kenneth C.} and Lini Pandite and Michael Robertson and Mary Kroon and Jerome Ritz and Nadler, {Lee M.}",
year = "1996",
month = "10",
day = "1",
language = "English (US)",
volume = "88",
pages = "2780--2786",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission

AU - Freedman, Arnold S.

AU - Gribben, John G.

AU - Neuberg, Donna

AU - Mauch, Peter

AU - Soiffer, Robert J.

AU - Anderson, Kenneth C.

AU - Pandite, Lini

AU - Robertson, Michael

AU - Kroon, Mary

AU - Ritz, Jerome

AU - Nadler, Lee M.

PY - 1996/10/1

Y1 - 1996/10/1

N2 - We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36% achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63% and 89% at 3 years, respectively, with a median follow- up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival.

AB - We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36% achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63% and 89% at 3 years, respectively, with a median follow- up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival.

UR - http://www.scopus.com/inward/record.url?scp=10144243981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10144243981&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 2780

EP - 2786

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -